首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名：Drug and therapeutics bulletin

缩写：

ISSN：0012-6543

e-ISSN：1755-5248

IF/分区：0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引979条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
AI and DTB : the computer says no [0.03%] AI和DTB：电脑说了不
David Phizackerley David Phizackerley
Editorial Drug and therapeutics bulletin. 2025 Jul 14:dtb-2025-000030. DOI:10.1136/dtb.2025.000030 2025
Impact of clinical pharmacists in primary care [0.03%] 临床药师在初级保健中的作用
Drug and therapeutics bulletin. 2025 Jul 2:dtb-2025-000028. DOI:10.1136/dtb.2025.000028 2025
▼ Abaloparatide (Eladynos) for osteoporosis [0.03%] 艾拉普塔肽（Eladynos）治疗骨质疏松症
Drug and therapeutics bulletin. 2025 Jun 30;63(7):103-108. DOI:10.1136/dtb.2024.000054 2025
NICE/BTS/SIGN asthma guidelines: a breath of fresh AIR [0.03%] NICE/BTS/ SIGN哮喘指南：AIR的全新诠释
Jo Congleton Jo Congleton
Editorial Drug and therapeutics bulletin. 2025 Jun 30;63(7):98. DOI:10.1136/dtb.2024.000076 2025
Effective medication reviews and deprescribing in primary care [0.03%] 基层医疗中的有效药物重整与减药实践
Drug and therapeutics bulletin. 2025 Jun 26:dtb-2025-000024. DOI:10.1136/dtb.2025.000024 2025
Can we improve information accompanying drug safety warnings? [0.03%] 我们可以改善伴随药物安全警告的信息吗？
Julian Treadwell Julian Treadwell
Editorial Drug and therapeutics bulletin. 2025 Jun 19:dtb-2024-000051. DOI:10.1136/dtb.2024.000051 2025
Allopurinol fails to improve heart disease outcomes [0.03%] 阿洛普尿未能改善心脏病预后
Drug and therapeutics bulletin. 2025 Jun 6:dtb-2025-000021. DOI:10.1136/dtb.2025.000021 2025
Tirzepatide for weight reduction in people without diabetes [0.03%] tirzepatide减重疗法用于无糖尿病人群
Drug and therapeutics bulletin. 2025 Jun 3:dtb-2025-000018. DOI:10.1136/dtb.2025.000018 2025
Risk of secondary T-cell malignancy after CAR T-cell therapy [0.03%] CAR-T细胞治疗后继发T细胞恶性肿瘤的风险
Drug and therapeutics bulletin. 2025 Jun 3:dtb-2025-000023. DOI:10.1136/dtb.2025.000023 2025
Medical management of ADHD in adults: part 2 [0.03%] 成人注意缺陷多动障碍的药物治疗（第二部分）
Laurence Leaver Laurence Leaver
Methylphenidate and lisdexamfetamine are recommended as first-line pharmacological treatment options for adults with attention deficit hyperactivity disorder (ADHD). Formulations of methylphenidate can generally be classified into three gro...
Review Drug and therapeutics bulletin. 2025 Jun 3;63(6):85-93. DOI:10.1136/dtb.2025.000019 2025